menu
    • menu

    Company profile for Extrovis AG

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Extrovis is a global pharmaceutical company based in Switzerland with subsidiaries in Hungary and India. The Indian unit employs 60 scientists and researchers focused on developing complex APIs and finished dosage forms for pharmaceutical products. The company has established a presence in Hungary to support its plans for entering the European market and employs a team for supply chain, regulatory, pharmacovigilance and custom...
    Extrovis is a global pharmaceutical company based in Switzerland with subsidiaries in Hungary and India. The Indian unit employs 60 scientists and researchers focused on developing complex APIs and finished dosage forms for pharmaceutical products. The company has established a presence in Hungary to support its plans for entering the European market and employs a team for supply chain, regulatory, pharmacovigilance and customer service. Extrovis' portfolio includes niche generic products, products with formulation improvements, and redesigned products for patient safety and convenience, mostly as drug-device combinations.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Extrovis AGSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Bahnhof-Park 4, Baar 6340
    Telephone
    Telephone
    +41 799697055
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.extrovis.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/extrovis-pvt-ltd
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Extrovis & Dr Reddy’s launch Generic Fluorouracil Cream
    Extrovis & Dr Reddy’s launch Generic Fluorouracil Cream

    21 Aug 2025

    // PRESS RELEASE

    https://www.expresspharma.in/extrovis-ag-and-dr-reddys-launch-authorised-generic-fluorouracil-cream-0-5-per-cent-in-us-market/

    PRESS RELEASE
    21 Aug 2025
    Share Share
    Extrovis' Sugammadex Receives Approval in Europe
    Extrovis' Sugammadex Receives Approval in Europe

    16 Jun 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/sugammadex-adroiq-epar-medicine-overview_en.pdf

    EMA
    16 Jun 2023
    Share Share
    Extrovis' Lacosamide Adroiq (lacosamide) Receives Approval in Europe
    Extrovis' Lacosamide Adroiq (lacosamide) Receives Approval in Europe

    05 Jun 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/lacosamide-adroiq-epar-medicine-overview_en.pdf

    EMA
    05 Jun 2023
    Share Share
    Megasoft completed the acquisition of 40% stake in Extrovis AG.
    Megasoft completed the acquisition of 40% stake in Extrovis AG.

    19 Jan 2023

    // MARKET SCREENER

    https://www.marketscreener.com/quote/stock/MEGASOFT-LIMITED-6498580/news/Megasoft-Limited-completed-the-acquisition-of-40-stake-in-Extrovis-AG-42781952/

    MARKET SCREENER
    19 Jan 2023
    Share Share
    Megasoft Limited agreed to acquire 40% stake in EXTROVIS AG for $16 million.
    Megasoft Limited agreed to acquire 40% stake in EXTROVIS AG for $16 million.

    15 May 2022

    // MARKETSCREENER

    https://www.marketscreener.com/quote/stock/MEGASOFT-LIMITED-6498580/news/Megasoft-Limited-agreed-to-acquire-40-stake-in-EXTROVIS-AG-for-16-million-40454341/

    MARKETSCREENER
    15 May 2022
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Extrovis, Dr Reddy’s Launch Generic Fluorouracil Cream 0.5% In U.S. (52926 DU)

    Details:

    Fluorouracil inhibits fungal DNA and RNA synthesis, is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.


    Lead Product(s): Fluorouracil

    Therapeutic Area: Dermatology Brand Name: Carac-Generic

    Study Phase: Approved FDFProduct Type: Cytotoxic Drug

    Sponsor: Dr. Reddy\'s Laboratories

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 20, 2025

    blank

    01

    Extrovis AG

    Switzerland
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Extrovis AG

    Switzerland
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fluorouracil

    Therapeutic Area : Dermatology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Dr. Reddy\'s Laboratories

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Extrovis, Dr Reddy’s Launch Generic Fluorouracil Cream 0.5% In U.S. (52926 DU)

    Details : Fluorouracil inhibits fungal DNA and RNA synthesis, is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.

    Product Name : Carac-Generic

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    August 20, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Services

    Upload your portfolio for free, ask us

    API Manufacturing

    Click here to discover the service providers for API Manufacturing

    API & Drug Product Development

    Click here to discover the service providers for API & Drug Product Development

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Contact Extrovis AG and get a quotation

    Extrovis AG is a supplier offers 8 products (APIs, Excipients or Intermediates).

    Find a price of Dapsone bulk with DMF, CEP offered by Extrovis AG

    Find a price of Calcium Gluconate bulk with DMF offered by Extrovis AG

    Find a price of Eltrombopag bulk with DMF offered by Extrovis AG

    Find a price of Potassium Dihydrogen Phosphate bulk with DMF offered by Extrovis AG

    Find a price of Potassium Phosphate bulk with DMF offered by Extrovis AG

    Find a price of Tolvaptan bulk with DMF offered by Extrovis AG

    Find a price of Trabectedin bulk with DMF offered by Extrovis AG

    Find a price of Sugammadex Sodium bulk offered by Extrovis AG

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search